Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2012; 18(17): 2067-2075
Published online May 7, 2012. doi: 10.3748/wjg.v18.i17.2067
Published online May 7, 2012. doi: 10.3748/wjg.v18.i17.2067
Table 3 Distribution of patients according to the irritable bowel syndrome severity score classes n (%)
| Placebo (n = 25) | LCR35 (n = 25) | |
| Baseline IBS severity score (V2) | ||
| 150-300 (moderate symptoms) | 25 (100.0) | 25 (100.0) |
| Post-treatment IBS severity score (V3) | ||
| 0-150 (mild symptoms) | 12 (48.0) | 8 (32.0) |
| 150-300 (moderate symptoms) | 8 (32.0) | 13 (52.0) |
| > 300 (severe symptoms) | 5 (20.0) | 4 (16.0) |
| IBS severity score at the end of study (V4) | ||
| 0-150 (mild symptoms) | 9 (36.0) | 6 (24.0) |
| 150-300 (moderate symptoms) | 8 (32.0) | 13 (52.0) |
| > 300 (severe symptoms) | 8 (32.0) | 6 (24.0) |
- Citation: Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study. World J Gastroenterol 2012; 18(17): 2067-2075
- URL: https://www.wjgnet.com/1007-9327/full/v18/i17/2067.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i17.2067